DMTK DermTech
- 0.629
- +0.012+2.01%
- 0.627
- -0.002-0.32%
DermTech News
What Analysts Are Saying About DermTech Stock
DermTech (NASDAQ:DMTK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent ratings by
Express News | Lake Street Downgrades DermTech to Hold, Announces $0.63 Price Target
DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.
DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.
Express News | Stephens & Co. Reiterates Equal-Weight on DermTech, Maintains $1.5 Price Target
Express News | DermTech Inc : Btig Cuts to Neutral From Buy: Btig Cuts to Neutral From Buy
DermTech Cut to Neutral From Buy by BTIG
DermTech Cut to Neutral From Buy by BTIG
Express News | BTIG Downgrades DermTech to Neutral
DermTech (DMTK) Was Downgraded to a Hold Rating at BTIG
DermTech to Slash 56% of Workforce, Explore Options
By Ben Glickman DermTech said Thursday that it plans to cut more than half of its workforce as it explores strategic alternatives, its third round of layoffs in less than a year. The San Diego-based
Express News | DermTech Inc: Intends to Continue Laboratory Operations During Strategic Review
Express News | DermTech Inc - Company Anticipates Incurring a One-Time Restructuring Charge of Approximately $1.6 Mln in Q2 of 2024
Express News | DermTech Inc - Restructuring Actions Will Result in a Workforce Reduction of Approximately 100 Employees
Express News | DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effe
BTIG Remains a Buy on DermTech (DMTK)
Express News | DermTech Presents Research Abstracts At 2024 AAD Annual Meeting And New Research Published In Journal Of Investigative Dermatology
DermTech Is Maintained at Buy by BTIG
DermTech Is Maintained at Buy by BTIG
Express News | BTIG Maintains Buy on DermTech, Lowers Price Target to $2
DermTech Is Maintained at Equal-Weight by Stephens & Co.
DermTech Is Maintained at Equal-Weight by Stephens & Co.
Express News | Stephens & Co. Maintains Equal-Weight on DermTech, Lowers Price Target to $1.5
Analysis
Price Target
No Data
